<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28362">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02737501</url>
  </required_header>
  <id_info>
    <org_study_id>AP26113-13-301</org_study_id>
    <nct_id>NCT02737501</nct_id>
  </id_info>
  <brief_title>ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in ALK-positive Advanced Non-Small Cell Lung Cancer Patients</brief_title>
  <acronym>ALTA-1L</acronym>
  <official_title>A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ariad Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ariad Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in
      ALK-positive Advanced Lung Cancer Patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this phase III, randomized, open-label, comparative, multicenter,
      international study is to compare the efficacy and safety of brigatinib to that of
      crizotinib in anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic
      non-small cell lung cancer (NSCLC) patients who have not previously been treated with an ALK
      inhibitor. Participants will be randomized in a 1:1 ratio to receive either brigatinib, 90
      milligrams (mg) orally once daily (QD) for 7 days, then a 180 mg orally QD, or crizotinib,
      250 mg orally twice daily (BID). Participants will receive treatment until disease
      progression, intolerable toxicity, consent withdrawal, or death. The total estimated
      duration of the study is at least 5 years, including 2 years to accrue patients, with at
      least 3 years for treatment and follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS) as assessed by a blinded Independent Review Committee (bIRC)</measure>
    <time_frame>At least 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>At least 36 months</time_frame>
    <description>Defined as the proportion of the patients who are confirmed to have achieved CR or PR using RECIST v. 1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial ORR</measure>
    <time_frame>At least 36 months</time_frame>
    <description>Defined as the proportion of the patients who have achieved CR or PR in the CNS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial PFS</measure>
    <time_frame>At least 36 months</time_frame>
    <description>Defined as the time from randomization until first CNS disease progression is documented, or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>At least 36 months.</time_frame>
    <description>Defined as the time from randomization until death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (HRQoL)</measure>
    <time_frame>Until 30 days after the last dose of study treatment.</time_frame>
    <description>Defined as the perceived quality of the patient's life, which includes self-reported multidimensional measures of physical and mental health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with adverse events</measure>
    <time_frame>Until at least 30 days after the last dose of study treatment.</time_frame>
    <description>To evaluate the safety and tolerability of brigatinib in the Intention to Treat (ITT) population. Measured by routine physical and laboratory evaluations, ECG, and adverse event (AE) monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady state pharmacokinetic (PK) parameter: Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>Up to 28 months.</time_frame>
    <description>PK samples will be taken to assess limited elements of PK in the Treated population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady state pharmacokinetic (PK) parameter: Minimum plasma concentration [Cmin]</measure>
    <time_frame>Up to 28 months.</time_frame>
    <description>PK samples will be taken to assess limited elements of PK in the Treated population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady state pharmacokinetic (PK) parameter: Area Under the Curve [AUC]</measure>
    <time_frame>Up to 28 months.</time_frame>
    <description>PK samples will be taken to assess limited elements of PK in the Treated population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady state pharmacokinetic (PK) parameter: Time to maximum plasma concentration (Tmax)</measure>
    <time_frame>Up to 28 months.</time_frame>
    <description>PK samples will be taken to assess limited elements of PK in the Treated population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady state pharmacokinetic (PK) parameter: Apparent oral clearance [CL/F]</measure>
    <time_frame>Up to 28 months.</time_frame>
    <description>PK samples will be taken to assess limited elements of PK in the Treated population.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Advanced Malignancies</condition>
  <condition>Carcinoma</condition>
  <arm_group>
    <arm_group_label>Brigatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brigatinib will be administered orally to eligible patients with locally advanced or metastatic ALK+ NSCLC naïve to ALK inhibitors at a dose of 90 mg QD for 7 days, then 180 mg QD, continuously, with or without food until disease progression, unacceptable toxicity, withdrawal of consent or death.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crizotinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Crizotinib will be administered to eligible patients with locally advanced or metastatic ALK+ NSCLC naïve to ALK inhibitors as 250 mg orally BID, with or without food until disease progression, unacceptable toxicity, withdrawal of consent or death.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brigatinib</intervention_name>
    <description>Brigatinib will be administered orally to eligible patients with locally advanced or metastatic ALK+ NSCLC naïve to ALK inhibitors at a dose of 90 mg QD for 7 days, then 180 mg QD, continuously, until disease progression, unacceptable toxicity, withdrawal of consent or death.</description>
    <arm_group_label>Brigatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xalkori (crizotinib)</intervention_name>
    <description>Crizotinib will be administered to eligible patients with locally advanced or metastatic ALK+ NSCLC naïve to ALK inhibitors as 250 mg orally BID, until disease progression, unacceptable toxicity, withdrawal of consent or death.</description>
    <arm_group_label>Crizotinib</arm_group_label>
    <other_name>Crizotinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have histologically or cytologically confirmed stage IIIB (and not a candidate for
             definitive multimodality therapy) or stage IV NSCLC.

          2. Must have documented ALK rearrangement.

          3. Have sufficient tumor tissue available for central analysis.

          4. Have at least 1 measurable (i.e., target) lesion per RECIST v1.1.

          5. Recovered from toxicities related to prior anticancer therapy to NCI CTCAE v 4.0
             grade ≤1.

          6. Are a male or female patient ≥18 years old.

          7. Have adequate organ function, as defined by the study protocol.

          8. Have Eastern Cooperative Oncology Group (ECOG) performance status ≤2.

          9. Have normal QT interval on screening ECG evaluation, defined as QT interval corrected
             (Fridericia) (QTcF) of ≤450 milliseconds (msec) in males or ≤470 msec in females.

         10. For female patients of childbearing potential, have a negative pregnancy test
             documented prior to randomization.

         11. For female and male patients who are fertile, agree to use a highly effective form of
             contraception, as defined by the study protocol.

         12. Provide signed and dated informed consent indicating that the patient has been
             informed of all pertinent aspects of the study, including the potential risks, and is
             willingly participating.

         13. Have the willingness and ability to comply with scheduled visit and study procedures.

        Exclusion Criteria:

          1. Previously received an investigational antineoplastic agent for NSCLC.

          2. Previously received any prior TKI, including ALK-targeted TKIs.

          3. Previously received more than 1 regimen of systemic anticancer therapy for locally
             advanced or metastatic disease.

          4. Received chemotherapy or radiation within 14 days of first dose of study drug, except
             stereotactic radiosurgery (SRS) or stereotactic body radiation therapy (SBRT).

          5. Received anti-neoplastic monoclonal antibodies within 30 days of the first dose of
             study drug.

          6. Had major surgery within 30 days of the first dose of study drug, minor surgical
             procedures such as catheter placement or minimally invasive biopsies are allowed.

          7. Have been diagnosed with another primary malignancy other than NSCLC, except for
             adequately treated non-melanoma skin cancer or cervical cancer in situ; definitively
             treated non-metastatic prostate cancer; or patients with another primary malignancy
             who are definitively relapse-free with at least 3 years elapsed since the diagnosis
             of the other primary malignancy.

          8. Have symptomatic CNS metastases (parenchymal or leptomeningeal) at screening or
             asymptomatic disease requiring an increasing dose of corticosteroids to control
             symptoms within 7 days prior to randomization.

          9. Have current spinal cord compression (symptomatic or asymptomatic and detected by
             radiographic imaging). Patients with leptomeningeal disease and without cord
             compression are allowed.

         10. Be pregnant, planning a pregnancy, or breastfeeding

         11. Have significant, uncontrolled, or active cardiovascular disease, as defined by the
             study protocol.

         12. Have uncontrolled hypertension.

         13. Have a history or the presence at baseline of pulmonary interstitial disease,
             drug-related pneumonitis, or radiation pneumonitis.

         14. Have an ongoing or active infection.

         15. Have a known history of human immunodeficiency virus (HIV) infection.

         16. Have a known or suspected hypersensitivity to brigatinib or its excipients and/or
             crizotinib or its excipients.

         17. Have malabsorption syndrome or other gastrointestinal (GI) illness or condition.

         18. Have any condition or illness that, in the opinion of the investigator, would
             compromise patient safety or interfere with the evaluation of the study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David Kerstein, MD</last_name>
    <phone>(617) 494-0400</phone>
    <email>David.Kerstein@ARIAD.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sergio Santillana, MD</last_name>
    <phone>(617) 494-0400</phone>
    <email>Sergio.Santillana@ARIAD.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kaiser Permanente Southern California, Site #208</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Han Koh, MD</last_name>
      <phone>818-592-2480</phone>
    </contact>
    <contact_backup>
      <last_name>James Chow</last_name>
      <phone>619-528-6832</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Camidge, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center, Site #033</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Ferencz</last_name>
      <phone>203-200-4455</phone>
    </contact>
    <investigator>
      <last_name>Scott Gettinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center, Site #241</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric S Zetka</last_name>
      <phone>305-243-5185</phone>
    </contact>
    <investigator>
      <last_name>Mohammad Jahanzeb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center, Site #031</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Costa, MD</last_name>
      <phone>617-667-4249</phone>
    </contact>
    <contact_backup>
      <last_name>Heena Patel</last_name>
      <phone>617-667-4249</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>West Michigan Cancer Center, Site #242</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rick Sedlack</last_name>
      <phone>269-373-7470</phone>
    </contact>
    <investigator>
      <last_name>Sunil Nagpal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center, Site #038</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Balazs Halmos, MD</last_name>
      <phone>718-405-8510</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novant Presbyterian Medical Center (Site 205)</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Savage</last_name>
      <phone>704-384-5133</phone>
    </contact>
    <investigator>
      <last_name>William Mitchell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute Site #056</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Carrizosa, MD</last_name>
      <phone>704-355-5142</phone>
    </contact>
    <contact_backup>
      <last_name>Ryan Bender</last_name>
      <phone>704-355-5142</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma, Site #028</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad Razaq, MD</last_name>
      <phone>405-271-2604</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates (Site 244)</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76177</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terry Patton</last_name>
      <phone>763-712-2177</phone>
    </contact>
    <investigator>
      <last_name>Deborah Lindquist, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, Site #239</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76177</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajini K Malisetti, MD</last_name>
      <phone>763-712-2177</phone>
    </contact>
    <contact_backup>
      <last_name>Terry Patton</last_name>
      <phone>817-837-8676</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care (Site 114)</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76177</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terry Patton</last_name>
      <phone>763-712-2177</phone>
    </contact>
    <investigator>
      <last_name>David Waterhouse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers - Boulder (Site 191)</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76177</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Fleagle, MD</last_name>
      <phone>763-712-2177</phone>
    </contact>
    <contact_backup>
      <last_name>Terry Patton</last_name>
      <phone>763-712-2177</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute (Site 043)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rian Davis</last_name>
      <phone>801-585-0272</phone>
    </contact>
    <investigator>
      <last_name>Shiven Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Viriginia Cancer Specialists, PC (Site 238)</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander I Spira, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital, Pharmacy, Site #406</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Hotong</last_name>
      <phone>61-2-8382-3811</phone>
    </contact>
    <investigator>
      <last_name>Rachel Dear, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gosford Hospital Central Coaast Cancer Centre, Site #402</name>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Wong, MD</last_name>
      <phone>61-02-4320-5548</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital, Site #941</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick Pavlakis, MD</last_name>
      <phone>94631127</phone>
    </contact>
    <contact_backup>
      <last_name>Lindsey Griffiths</last_name>
      <phone>94631127</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital, Site #997</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Moore, MD</last_name>
      <phone>61-3-9231-3165</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Frankston Hospital, Site #994</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vinod Ganju, MBBS</last_name>
      <phone>61 (0) 39781-2611</phone>
    </contact>
    <contact_backup>
      <last_name>Ash Fazli</last_name>
      <phone>61 (0) 39781-2611</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Monash Cancer Centre Site #425</name>
      <address>
        <city>Bentleigh East</city>
        <zip>VIC 3165</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammad Alamgeer, MD</last_name>
      <phone>03 99288754</phone>
    </contact>
    <contact_backup>
      <last_name>Obaid Fazli</last_name>
      <phone>03 99288754</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St George Hospital Site #403</name>
      <address>
        <city>Kogarah</city>
        <zip>NSW 2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chee K Lee, MD</last_name>
      <phone>61 2 9113 4834</phone>
    </contact>
    <contact_backup>
      <last_name>Jimmy Vien</last_name>
      <phone>61 2 9113 4834</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum St. Polten (Site 462)</name>
      <address>
        <city>St. Polten</city>
        <zip>3100</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boban Stamenkovic</last_name>
      <phone>02742 300 14106</phone>
    </contact>
    <investigator>
      <last_name>Martin Wiesholzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SMZ Baumgartner Hohe, Otto-Wagner-Spital (Site 612)</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophia Holzer</last_name>
      <phone>00 43 (0)1 91 060 41135</phone>
    </contact>
    <investigator>
      <last_name>Otto Burghuber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen, Site #461</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rainer Kolb, MD</last_name>
      <phone>00 43 0 7242 415 2382</phone>
    </contact>
    <contact_backup>
      <last_name>Andrea Ringl</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre, Site #083</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>MG5 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Belling Leung</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>4684</phone_ext>
    </contact>
    <investigator>
      <last_name>Geoffrey Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital (Site 615)</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Mawn</last_name>
      <phone>(+45) 29165083</phone>
    </contact>
    <investigator>
      <last_name>Karin Hansen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital Pharmacy, Site #467</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jarkko Ahvonen, MD</last_name>
      <phone>00358 (0) 331165159</phone>
    </contact>
    <contact_backup>
      <last_name>Minna Patala</last_name>
      <phone>00358(0)331165159</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse (Site 568)</name>
      <address>
        <city>Caen</city>
        <state>Cedex 05</state>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabienne Divanon</last_name>
      <phone>33231455299</phone>
    </contact>
    <investigator>
      <last_name>Radj Gervais, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard (Site 746)</name>
      <address>
        <city>Lyon</city>
        <state>Rhone Alpes</state>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Engel</last_name>
      <phone>04 78 78 26 33</phone>
    </contact>
    <investigator>
      <last_name>Maurice Perol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest - Hopital Morvan (Site 523)</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin R Rubio</last_name>
      <phone>33298223102</phone>
    </contact>
    <investigator>
      <last_name>Renaud Descourt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Creteil (Site 469)</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Poullain</last_name>
      <phone>33(0)145175136</phone>
    </contact>
    <investigator>
      <last_name>Christos Chouaid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble - Hopital Albert Michallon (Site 569)</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis Moro-Sibilot, MD</last_name>
      <phone>33(0)476769209</phone>
    </contact>
    <contact_backup>
      <last_name>Audrey Lehmann</last_name>
      <phone>33(0)476769209</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hopital Nord, Pharmacie (Site 567)</name>
      <address>
        <city>Marseille</city>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Castro</last_name>
      <phone>04 91 96 87 76</phone>
    </contact>
    <investigator>
      <last_name>Fabrice Barlesi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne (Site 570)</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josiane Otto</last_name>
      <phone>04 92 03 10 11</phone>
    </contact>
    <contact_backup>
      <last_name>Emmanuel Besrest</last_name>
      <phone>04 92 03 10 11</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen - Hopital Charles Nicolle (Site 585)</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Donnadieu</last_name>
      <phone>02-32-88-82-07</phone>
    </contact>
    <investigator>
      <last_name>Luc Thiberville, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Ludwig-Maximilian-Universitat Munchen (Site 609)</name>
      <address>
        <city>Munchen</city>
        <state>Bayern</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astrid Borgmeier</last_name>
      <phone>4989440055393</phone>
    </contact>
    <investigator>
      <last_name>Rudolf Huber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evangelische Lungenklinik Berlin, Site #588</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norman Golchert</last_name>
      <phone>493094802569</phone>
    </contact>
    <investigator>
      <last_name>Christian Grohe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital for Lung Disease Cologne Merheim Site #626</name>
      <address>
        <city>Cologne</city>
        <zip>51100</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walburga Engel-Riedel, MD</last_name>
      <phone>49221890713962</phone>
    </contact>
    <contact_backup>
      <last_name>Gudrun Klauke</last_name>
      <phone>49221890713962</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Freiburg (Site 527)</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Bubritzki</last_name>
      <phone>4976127073615</phone>
    </contact>
    <investigator>
      <last_name>Cornelius Waller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik Heidelberg Site #586</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helge Bischoff, MD</last_name>
      <phone>4962213967638</phone>
    </contact>
    <contact_backup>
      <last_name>Katharina Wegner</last_name>
      <phone>4962213967638</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Lungenklinik Hemer, Site #620</name>
      <address>
        <city>Hemer</city>
        <zip>58675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Serke, MD</last_name>
      <phone>4923729082167</phone>
    </contact>
    <contact_backup>
      <last_name>Melanie Holstein</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Site #472</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Ritgen, MD</last_name>
      <phone>494315973667</phone>
    </contact>
    <contact_backup>
      <last_name>Bettina Freymark</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Pius-Hospital Oldenburg, Universitätsklinik für Strahlentherapie, Site #587</name>
      <address>
        <city>Oldenburg</city>
        <zip>26121</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Griesinger, MD</last_name>
      <phone>494412291229</phone>
    </contact>
    <contact_backup>
      <last_name>Doris Ahrens</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Studiengesellschaft Hamato-Onkologie Hamburg (Site 473)</name>
      <address>
        <city>Oststeinbek</city>
        <zip>22113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerstin Harder</last_name>
      <phone>497127373</phone>
    </contact>
    <investigator>
      <last_name>Eckart Laack, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital, Department of Oncology, Site #986</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor H Lee, MD</last_name>
      <phone>852 2255 6729</phone>
    </contact>
    <contact_backup>
      <last_name>Edmond Cheng</last_name>
      <phone>852 2255 6729</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital, Division of Respiratory Disease Site #973</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James C Ho, MD</last_name>
      <phone>852 2255 6729</phone>
    </contact>
    <contact_backup>
      <last_name>Edmund Cheng</last_name>
      <phone>852 2255 6729</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital (Site 987)</name>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Yip</last_name>
      <phone>3506 8170</phone>
    </contact>
    <investigator>
      <last_name>Yu Chung Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tuen Mun Hospital (Site 426)</name>
      <address>
        <city>Tuen Mun</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sing H Lo, MD</last_name>
      <phone>24685111</phone>
      <phone_ext>3397</phone_ext>
    </contact>
    <contact_backup>
      <phone>24685111</phone>
      <phone_ext>3397</phone_ext>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>A.O.S.G. Moscati, Site #477</name>
      <address>
        <city>Avellino</city>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cesare Gridelli, MD</last_name>
      <phone>390825203878</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CRO Aviano (Site 624)</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Bearz, MD</last_name>
      <phone>+39(0)434 659837</phone>
    </contact>
    <contact_backup>
      <last_name>Sara Cecco</last_name>
      <phone>+39(0)434 659837</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>IRCCS Giovanni Paolo II (Site 481)</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrizia Nardulli</last_name>
      <phone>390805556942</phone>
    </contact>
    <investigator>
      <last_name>Andrea Misino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico S.Orsola-Malpighi Site #784</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Ardizzoni, MD</last_name>
      <phone>+39 (0)51 2143049</phone>
    </contact>
    <contact_backup>
      <last_name>Primoz Juric</last_name>
      <phone>+39 (0)51 2143049</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>IRST, Farmacia Oncologica IRST IRCCS (Site 575)</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Maugeri</last_name>
      <phone>39(0)543739968</phone>
    </contact>
    <investigator>
      <last_name>Angelo Delmonte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele (Site 578)</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Vecchione</last_name>
      <phone>+39(0)226435619</phone>
    </contact>
    <investigator>
      <last_name>Lucas Gianni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Ocologia (Site 608)</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Costantino Jemos</last_name>
      <phone>39 (0)2 57489017</phone>
    </contact>
    <investigator>
      <last_name>Filippo de Marinis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Fondazione Giovanni Pascale, Site #478</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Morabito</last_name>
      <phone>390815903686</phone>
    </contact>
    <contact_backup>
      <last_name>Roberto D-Aniello</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica Azienda Ospedaliera - Universitaria di Parma (Site 607)</name>
      <address>
        <city>Parma</city>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Zanardi</last_name>
      <phone>39 (0)521 702130</phone>
    </contact>
    <investigator>
      <last_name>Marcello Tiseo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. di Perugia - Ospedale S. Maria della Misericordia Site #476</name>
      <address>
        <city>Perugia</city>
        <zip>06132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Chiari, MD</last_name>
      <phone>390755783751</phone>
    </contact>
    <contact_backup>
      <last_name>Brunella Pochini</last_name>
      <phone>390755783751</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>P.O. di Livorno, Farmacia Oncologica (Site 479)</name>
      <address>
        <city>Ravenna</city>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Rondoni</last_name>
      <phone>39 (0)544285743</phone>
    </contact>
    <investigator>
      <last_name>Federico Cappuzzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Bio Medico (Site 767)</name>
      <address>
        <city>Roma</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Sironi</last_name>
      <phone>39 06 225411618</phone>
    </contact>
    <investigator>
      <last_name>Giuseppe Tonini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severence Hospital, Yonsei University Health System, Site # 913</name>
      <address>
        <city>Seodaemun-gu</city>
        <state>Seoul</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hye-Ryun Kim, MD</last_name>
      <phone>82-2-2228-0511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center, Center for Lung Cancer, Site #916</name>
      <address>
        <city>Ilsan</city>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji Y Han, MD</last_name>
      <phone>82-31-920-0224</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital, Site #408</name>
      <address>
        <city>Seongnam</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong S Lee, MD</last_name>
      <phone>82-31-787-3951</phone>
    </contact>
    <contact_backup>
      <last_name>Haein Kim</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital (SIte 424)</name>
      <address>
        <city>Seoul</city>
        <zip>0241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang sun Park</last_name>
      <phone>82-2-920-5362</phone>
    </contact>
    <investigator>
      <last_name>Sang Shin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital, Site #915</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong W Kim, MD</last_name>
      <phone>82-2-2072-7450</phone>
    </contact>
    <contact_backup>
      <last_name>Min K Kim</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center, Site #917</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hye M Lee</last_name>
      <phone>82-2-3010-6280</phone>
    </contact>
    <investigator>
      <last_name>Sang W Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center, Site #918</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seoyoung Hwang</last_name>
      <phone>82-2-3410-6096</phone>
    </contact>
    <investigator>
      <last_name>Myung J Ahn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea (Site 938)</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jungsun Lee</last_name>
      <phone>82-2-2258-2536</phone>
    </contact>
    <investigator>
      <last_name>Jin-Hyoung Kang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chungbuk National University Hospital, Site #407</name>
      <address>
        <city>Seowon</city>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ki H Lee, MD</last_name>
      <phone>82-43-269-6537</phone>
    </contact>
    <contact_backup>
      <last_name>Sohee Jeon</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Luxembourg Site #466</name>
      <address>
        <city>Luxembourg</city>
        <zip>L-1210</zip>
        <country>Luxembourg</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy Berchem, MD</last_name>
      <phone>352 4411-8880</phone>
    </contact>
    <contact_backup>
      <last_name>Valérie Arnoud</last_name>
      <phone>352 4411-8880</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen (UMCG) #581</name>
      <address>
        <city>Groningen</city>
        <state>AP</state>
        <zip>9713</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harry Groen, MD</last_name>
      <phone>0031-50-361-43-31</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute Site #579</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 EC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sjaak Burgers, MD</last_name>
      <phone>+31-20-5124481</phone>
    </contact>
    <contact_backup>
      <last_name>A.D.R Huitema</last_name>
      <phone>+31-20-5124481</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Amphia Hospital Site #483</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>K H van der Leest, MD</last_name>
      <phone>0031 76-5953720</phone>
    </contact>
    <contact_backup>
      <last_name>P V Hattum</last_name>
      <phone>0031 76-5953720</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Isala (Site 482)</name>
      <address>
        <city>Zwolle</city>
        <zip>8025</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thea van Herpen</last_name>
      <phone>31384243216</phone>
    </contact>
    <investigator>
      <last_name>J.A. Stigt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital, Site #630</name>
      <address>
        <city>Oslo</city>
        <zip>NO-0379</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aslaug Helland</last_name>
      <phone>47 22782306</phone>
    </contact>
    <contact_backup>
      <last_name>Siri Mork</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>National University Hospital, Site #405</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chin H Min, MD</last_name>
      <phone>6567725836</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Singapore (Site 989)</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ng Hui Cheng</last_name>
      <phone>64368034</phone>
    </contact>
    <investigator>
      <last_name>Daniel Tan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OncoCare Cancer Centre, Site #988</name>
      <address>
        <city>Singapore</city>
        <zip>258499</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vera Chen</last_name>
      <phone>65-673-37890</phone>
    </contact>
    <investigator>
      <last_name>Leong S Swan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Teresa Herrera Site #554</name>
      <address>
        <city>A Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria R Garcia-Campelo, MD</last_name>
      <phone>34981178000</phone>
    </contact>
    <contact_backup>
      <last_name>Maria M Salvador</last_name>
      <phone>34981178000</phone>
      <phone_ext>292858</phone_ext>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel Andres</last_name>
      <phone>0034 965933314</phone>
    </contact>
    <contact_backup>
      <last_name>Gracia Ferron</last_name>
      <phone>0034 965933314</phone>
    </contact_backup>
    <investigator>
      <last_name>Bartomeu Massuti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias I Pujol Site #512</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enric Carcereny, MD</last_name>
      <phone>34934978589</phone>
    </contact>
    <contact_backup>
      <last_name>Marta Munné</last_name>
      <phone>34934978589</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quiron Dexeus (Site 590)</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rocío Gil Partal</last_name>
      <phone>34 93 227 47 47</phone>
    </contact>
    <investigator>
      <last_name>Santiago Viteri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital, Site #503</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enriqueta Felip-Font, MD</last_name>
      <phone>34 93 274 60 17</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lucus Augusti (Site 488)</name>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Araceli I Santamaria</last_name>
      <phone>(34)982295554</phone>
    </contact>
    <investigator>
      <last_name>Serigio Vazquez Estevez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal (Site 538)</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Garrido, MD</last_name>
      <phone>34 91 336 82 63</phone>
    </contact>
    <contact_backup>
      <last_name>Cristina Pueyo</last_name>
      <phone>34 91 336 82 63</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre (Site 633)</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia de Amuriza</last_name>
      <phone>34 913908546</phone>
    </contact>
    <investigator>
      <last_name>Luis Paz-Ares Rodriguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz (Site 966)</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Gómez Salcedo</last_name>
      <phone>34912071471</phone>
    </contact>
    <investigator>
      <last_name>Javier de Castro, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro (Site 634)</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria de la Encina Higuera</last_name>
      <phone>34911916440</phone>
    </contact>
    <investigator>
      <last_name>Mariano Provencio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Malaga (Site 698)</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angeles R Souviron</last_name>
      <phone>0034 951291986</phone>
    </contact>
    <investigator>
      <last_name>Vanesa G Calderon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Mendez Castrillon</last_name>
      <phone>985 10 61 00</phone>
      <phone_ext>39711</phone_ext>
    </contact>
    <investigator>
      <last_name>Emilio Esteban Gonzalez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Valencia, Site #589</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amelia Insa, MD</last_name>
      <phone>34648071070</phone>
    </contact>
    <contact_backup>
      <last_name>Jose E Munoz</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset (Site 758)</name>
      <address>
        <city>Molnlycke</city>
        <zip>SE-435 33</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomas Olofsson</last_name>
      <phone>46104478730</phone>
    </contact>
    <investigator>
      <last_name>Jan Nyman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska Hospital, Site #763</name>
      <address>
        <city>Solna</city>
        <zip>17164</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Signe Friesland, MD</last_name>
      <phone>46851775309</phone>
    </contact>
    <contact_backup>
      <last_name>Agneta Segerlund</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital of Umeå (Site 495)</name>
      <address>
        <city>Umea</city>
        <zip>90737</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikael Johansson, MD</last_name>
      <phone>+46(0)907851833</phone>
    </contact>
    <contact_backup>
      <last_name>Ingvild Parnerud</last_name>
      <phone>+46(0)907851833</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur (Site 995)</name>
      <address>
        <city>Winterthur</city>
        <zip>8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatrice Brinkers</last_name>
      <phone>41 52 266 36 55</phone>
    </contact>
    <investigator>
      <last_name>Miklos Pless, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Zürich (Site 562)</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Curioni, MD</last_name>
      <phone>41 44 255 99 67</phone>
    </contact>
    <contact_backup>
      <last_name>Sabina Tresch</last_name>
      <phone>41 44 255 99 67</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital (Site 410)</name>
      <address>
        <city>Xitun</city>
        <state>Taichung</state>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nai-Yun Huang</last_name>
      <phone>04-23592525</phone>
      <phone_ext>1386</phone_ext>
    </contact>
    <investigator>
      <last_name>Gee-Chen Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital (Site 409)</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Te-Chun Hsia, MD</last_name>
      <phone>886-4-22052121</phone>
      <phone_ext>5355</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Fang-Yu Chen</last_name>
      <phone>886-4-22052121</phone>
      <phone_ext>5355</phone_ext>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital (Site 412)</name>
      <address>
        <city>Taipei City</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi-Chi Tseng</last_name>
      <phone>886-2-2312-3456</phone>
      <phone_ext>66049</phone_ext>
    </contact>
    <investigator>
      <last_name>Chih-Hsin Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital (Site 404)</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pao-Hsiang Chiu</last_name>
      <phone>886228712121</phone>
      <phone_ext>2939</phone_ext>
    </contact>
    <investigator>
      <last_name>Yuh-Min Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maidstone Hospital Site #496</name>
      <address>
        <city>Maidstone</city>
        <state>Kent</state>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Riyaz Shah, MD</last_name>
      <phone>01622 227090</phone>
    </contact>
    <contact_backup>
      <last_name>Ian Pamphlett</last_name>
      <phone>01622 227090</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary, Site #497</name>
      <address>
        <city>Leicester</city>
        <state>LE2</state>
        <zip>7LG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samreen Ahmed, MD</last_name>
      <phone>0116-258-6078</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCL Hospital, Site #628</name>
      <address>
        <city>London</city>
        <state>N7</state>
        <zip>9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dionysis Papadatos-Pastos, MD</last_name>
      <phone>0203-447-3020</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust (Site 584)</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Soma</last_name>
      <phone>0207 188 2006</phone>
    </contact>
    <investigator>
      <last_name>Sharmistha Ghosh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust Site #725</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raffaele Califano, MD</last_name>
      <phone>0161 918 7651</phone>
    </contact>
    <contact_backup>
      <last_name>Karina Osowska</last_name>
      <phone>0161 918 7651</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Luxembourg</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>March 6, 2017</lastchanged_date>
  <firstreceived_date>March 30, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>Non-small cell lung carcinoma</keyword>
  <keyword>Epithelial lung cancer</keyword>
  <keyword>Squamous cell carcinoma</keyword>
  <keyword>Large cell carcinoma</keyword>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Carcinoma</keyword>
  <keyword>Anaplastic Lymphoma Kinase (ALK)</keyword>
  <keyword>Advanced Cancers</keyword>
  <keyword>Brigatinib</keyword>
  <keyword>AP26113</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Crizotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
